COVID-19 Treatment Study for Non-Hospitalized Participants

A5407 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study measuring the clinical and antiviral effects of an oral medication in non-hospitalized participants with Covid-19. The study lasts 24 weeks and participants must be 18 years or older to participate. Study drug (or placebo) is taken for 5 consecutive days by mouth. Required activities from participants include completing symptom diaries and providing blood samples and both nasopharyngeal and anterior nasal swabs.

In order to participate you must meet the following criteria:

• Are 18 years of age or older.
• Have an active COVID-19 infection.

You will be excluded from the study if any of the following criteria apply to you:

• Are breastfeeding or pregnant.
• Are on dialysis or have a history of liver cirrhosis.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.